Cargando…

Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a complex disorder characterized by vascular remodeling and a consequent increase in pulmonary vascular resistance. The histologic hallmarks of PAH include plexiform and neointimal lesions of the pulmonary arterioles, which are composed of dysregulated, apopt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pullamsetti, Soni Savai, Sitapara, Ravikumar, Osterhout, Robin, Weiss, Astrid, Carter, Laura L., Zisman, Lawrence S., Schermuly, Ralph Theo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454154/ https://www.ncbi.nlm.nih.gov/pubmed/37628831 http://dx.doi.org/10.3390/ijms241612653

Ejemplares similares

Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension
por: Galkin, Anna, et al.
Publicado: (2022)

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
por: Frantz, Robert P., et al.
Publicado: (2021)

SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling
por: Sitapara, Ravikumar, et al.
Publicado: (2021)

Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension
por: Sitapara, Ravikumar, et al.
Publicado: (2021)

Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension
por: Sklepkiewicz, Piotr, et al.
Publicado: (2011)

Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer
por: Chelladurai, Prakash, et al.
Publicado: (2021)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives
por: Chelladurai, Prakash, et al.
Publicado: (2016)

Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β
por: Dahal, Bhola K., et al.
Publicado: (2011)

Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling
por: Tian, Xia, et al.
Publicado: (2011)

EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition
por: Pullamsetti, Soni Savai, et al.
Publicado: (2019)

Cancer and pulmonary hypertension: Learning lessons and real-life interplay
por: Pullamsetti, Soni Savai, et al.
Publicado: (2020)

Effects of anti-inflammatory vagus nerve stimulation on the cerebral microcirculation in endotoxinemic rats
por: Mihaylova, Stanka, et al.
Publicado: (2012)

Correction to: Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2022)

Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis
por: Nikolova, Sevdalina, et al.
Publicado: (2010)

New Insights into the Epigenomic Landscape of Small-Cell Lung Cancer: A Game Changer?
por: Sarode, Poonam, et al.
Publicado: (2022)

Correction to: Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis
por: Nikolova, Sevdalina, et al.
Publicado: (2022)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
por: Humbert, Marc, et al.
Publicado: (2019)

Osteopontin in Pulmonary Hypertension
por: Mamazhakypov, Argen, et al.
Publicado: (2023)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?
por: Pullamsetti, Soni Savai, et al.
Publicado: (2020)

Mechanics and mechanisms of pulmonary hypertension—Conference summary and translational perspectives
por: Seeger, Werner, et al.
Publicado: (2013)

Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans
por: Padmasekar, Manju, et al.
Publicado: (2021)

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
por: Pullamsetti, Soni, et al.
Publicado: (2005)

5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
por: Janssen, Wiebke, et al.
Publicado: (2015)

Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension
por: Kosanovic, Djuro, et al.
Publicado: (2019)

Long Noncoding RNAs: Emerging Regulators of Platelet-derived Growth Factor Signaling
por: Valasarajan, Chanil, et al.
Publicado: (2022)

Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury
por: Dumitrascu, Rio, et al.
Publicado: (2008)

Natural plant products in treatment of pulmonary arterial hypertension
por: Xiang, Lili, et al.
Publicado: (2018)

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
por: Dabral, Swati, et al.
Publicado: (2019)

Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf’s Skin?
por: Goncharova, Elena A., et al.
Publicado: (2021)

Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice
por: Gredic, Marija, et al.
Publicado: (2022)

Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?
por: Avci, Edibe, et al.
Publicado: (2022)

Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression
por: Karger, Annika, et al.
Publicado: (2021)

Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats
por: Dahal, Bhola K, et al.
Publicado: (2011)

Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension
por: Hu, Cheng‐Jun, et al.
Publicado: (2018)

Mechanisms of disease: pulmonary arterial hypertension
por: Schermuly, Ralph T., et al.
Publicado: (2011)

Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
por: Udalov, Sergey, et al.
Publicado: (2010)

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension
por: Chelladurai, Prakash, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ev5aifc3jvk4mns7gsnbvkf3hk